Market Closed -
Xetra
11:36:17 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
13.98
EUR
|
+0.43%
|
|
-1.96%
|
-11.85%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
384.5
|
601.6
|
787.3
|
400.4
|
377.6
|
332.8
|
-
|
-
|
Enterprise Value (EV)
1 |
375.1
|
601
|
668.6
|
342.4
|
377.6
|
495.3
|
370.6
|
407.7
|
P/E ratio
|
40.6
x
|
95.9
x
|
105
x
|
22.7
x
|
20.1
x
|
11.7
x
|
10.2
x
|
8.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.74
x
|
0.96
x
|
0.58
x
|
0.25
x
|
0.21
x
|
0.16
x
|
0.16
x
|
0.15
x
|
EV / Revenue
|
0.73
x
|
0.96
x
|
0.49
x
|
0.21
x
|
0.21
x
|
0.25
x
|
0.18
x
|
0.18
x
|
EV / EBITDA
|
22.9
x
|
39.8
x
|
17.4
x
|
6.24
x
|
6.24
x
|
5.99
x
|
3.9
x
|
3.49
x
|
EV / FCF
|
-148
x
|
-14.7
x
|
13
x
|
10.7
x
|
-
|
12.1
x
|
7.49
x
|
7.59
x
|
FCF Yield
|
-0.68%
|
-6.79%
|
7.72%
|
9.36%
|
-
|
8.25%
|
13.4%
|
13.2%
|
Price to Book
|
4.71
x
|
4.22
x
|
2.26
x
|
0.93
x
|
-
|
0.72
x
|
0.66
x
|
0.63
x
|
Nbr of stocks (in thousands)
|
14,564
|
16,085
|
20,265
|
22,881
|
23,806
|
23,806
|
-
|
-
|
Reference price
2 |
26.40
|
37.40
|
38.85
|
17.50
|
15.86
|
13.98
|
13.98
|
13.98
|
Announcement Date
|
4/8/20
|
3/31/21
|
3/29/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
516.8
|
626.5
|
1,357
|
1,611
|
1,785
|
2,020
|
2,114
|
2,263
|
EBITDA
1 |
16.37
|
15.1
|
38.44
|
54.88
|
60.51
|
82.73
|
95
|
116.7
|
EBIT
1 |
14.39
|
9.542
|
15.26
|
28.97
|
31.37
|
52.83
|
64.35
|
73.9
|
Operating Margin
|
2.78%
|
1.52%
|
1.12%
|
1.8%
|
1.76%
|
2.62%
|
3.04%
|
3.27%
|
Earnings before Tax (EBT)
1 |
14.22
|
8.901
|
13.58
|
27.82
|
29.37
|
43.4
|
58.33
|
64.95
|
Net income
1 |
9.76
|
6.064
|
7.402
|
18.33
|
18.81
|
29.54
|
39.59
|
44.05
|
Net margin
|
1.89%
|
0.97%
|
0.55%
|
1.14%
|
1.05%
|
1.46%
|
1.87%
|
1.95%
|
EPS
2 |
0.6500
|
0.3900
|
0.3700
|
0.7700
|
0.7900
|
1.195
|
1.369
|
1.725
|
Free Cash Flow
1 |
-2.539
|
-40.84
|
51.62
|
32.06
|
-
|
40.85
|
49.5
|
53.75
|
FCF margin
|
-0.49%
|
-6.52%
|
3.8%
|
1.99%
|
-
|
2.02%
|
2.34%
|
2.38%
|
FCF Conversion (EBITDA)
|
-
|
-
|
134.31%
|
58.42%
|
-
|
49.38%
|
52.1%
|
46.06%
|
FCF Conversion (Net income)
|
-
|
-
|
697.39%
|
174.91%
|
-
|
138.28%
|
125.02%
|
122.02%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/8/20
|
3/31/21
|
3/29/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
-
|
353.9
|
368.6
|
393
|
399.2
|
419.2
|
EBITDA
1 |
18.26
|
9.943
|
10.23
|
14.14
|
14.32
|
15.3
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
5.418
|
-
|
7.588
|
-
|
8.594
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
0.2100
|
-
|
0.2500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/12/21
|
11/9/21
|
3/29/22
|
5/11/22
|
8/11/22
|
11/10/22
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
162
|
37.8
|
74.9
|
Net Cash position
1 |
9.38
|
0.55
|
119
|
58
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
1.964
x
|
0.3982
x
|
0.6418
x
|
Free Cash Flow
1 |
-2.54
|
-40.8
|
51.6
|
32.1
|
-
|
40.9
|
49.5
|
53.8
|
ROE (net income / shareholders' equity)
|
12.8%
|
5.41%
|
2.76%
|
4.35%
|
-
|
5.3%
|
6.93%
|
8.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
2.06%
|
3.33%
|
-
|
4.25%
|
4.68%
|
-
|
Assets
1 |
-
|
-
|
359.3
|
550.1
|
-
|
694.4
|
846.2
|
-
|
Book Value Per Share
2 |
5.600
|
8.850
|
17.20
|
18.80
|
-
|
19.40
|
21.10
|
22.10
|
Cash Flow per Share
2 |
-
|
-
|
3.050
|
1.560
|
-
|
2.450
|
2.400
|
3.260
|
Capex
1 |
2.09
|
2.72
|
9.9
|
5.06
|
-
|
9.05
|
9.27
|
17.3
|
Capex / Sales
|
0.4%
|
0.43%
|
0.73%
|
0.31%
|
-
|
0.45%
|
0.44%
|
0.76%
|
Announcement Date
|
4/8/20
|
3/31/21
|
3/29/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
13.98
EUR Average target price
34.75
EUR Spread / Average Target +148.57% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.85% | 355M | | +26.08% | 681B | | +21.85% | 556B | | -4.77% | 361B | | +16.97% | 325B | | +5.69% | 285B | | +13.68% | 235B | | +3.65% | 199B | | -11.12% | 189B | | -3.40% | 157B |
Other Pharmaceuticals
|